The Effect of Carrier Material on the Measured Resistance of Spores - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

The Effect of Carrier Material on the Measured Resistance of Spores
A biological indicator (BI) measures the effectiveness of the sterilization process to which it is subjected. Factors such as the test organism, the packaging, the culture material, and the test system all influence a BI's resistance. Carrier material is an often-overlooked factor that also influences BI resistance. The authors examine various solid and liquid carriers, describe their properties, and investigate how they influence BI resistance.


Pharmaceutical Technology


Liquid carriers


Figure 13
Liquid-carrier BIs generally consist of hermetically sealed glass ampuls filled with the inoculated liquid, which usually is a culture medium. The physical and chemical properties of the liquid influence spore resistance. Properties such as pH, ionic strength, the concentration of active ingredients, and the viscosity of these liquids can cause spores to clump. Spore clumping may lead to erratic results and higher resistance. The effect of pH is demonstrated by phase-contrast microscopy in Figures 13–15. Changes in the pH of some liqu-ids may cause spores to form aggregates. As the pH shifts from neutral to acidic, the spores may form larger aggregates. The size of the aggregates can protect spores in the center of these clusters, which results in a higher observed resistance. This resistance cannot be considered an artifact of experimental error because the chemistry of the liquid has a similar effect on the bioburden that naturally occurs in the product.


Figure 14
A survivor-curve test performed on clumped spores in a pharmaceutical product resulted in a rapid drop in population during the initial phase (i.e., the death of single spores or small clumps), followed by tailing because of the presence of large clumps of spores. (see Figure 16). Data such as these initially may seem troublesome, but they are critical when developing a product-sterilization cycle.

Liquid pharmaceutical product inoculated with spores used in BIs


Figure 15
The liquid spore carrier of a BI can be the pharmaceutical product itself. The excipients and active ingredients both can affect resistance. D-value studies performed on aqueous-based pharmaceutical products demonstrate that, in most cases, concentrations of active ingredients have little influence on the D-value. These results indicate that the excipients have the greatest impact on BI resistance. Test units using the same spores suspended in water for injection were prepared as a comparison (see Table III).


Figure 16
In the light of new and emerging materials and sterilization technologies, it is important to understand that spores are the only tool that can measure the lethality of a sterilization process effectively. Spores account for the substrate effect and the critical process parameters of the sterilization process itself.


ADVERTISEMENT

RELATED CONTENT
The Role of Glasses in Aseptic Production: A Detail Often Ignored
Risk-Management Assessment of Visible-Residue Limits in Cleaning Validation
The Effect of Carrier Material on the Measured Resistance of Spores
The Importance of Pre-Use Integrity Testing in Sterilizing Filtration
Radiation Sterilization of Parenterals
blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
21%
To all process for new products only
13%
To select process for new products only
26%
To select processes for both new and legacy products
21%
Do not use QbD
21%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
Overcoming the Challenges in Biopharmaceutical Stability Testing
PhRMA Dismayed by Special 301 Report
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here